A freeze-dried, platelet-derived hemostatic agent (FPH) restored hemostasis in humanized mice infused with DAPT-exposed platelets, reducing the fraction of bleeding tails at 10 minutes from 60% to 5%.
Does an investigational prohemostatic agent restore hemostatic properties in platelets from patients on dual antiplatelet therapy?
An investigational prohemostatic agent can restore hemostasis in the setting of DAPT and is reversible with a thrombin inhibitor, offering a potential strategy for managing DAPT-associated bleeding.
Absolute Event Rate: 5% vs 60%
p-value: p=<0.001
This preclinical evaluation of a prohemostatic agent involved patients who received aspirin and clopidogrel before coronary artery stenting, the use of a humanized animal model to assess the hemostatic properties of patient platelets, as well as microfluidic assays to measure platelet reactivity. We demonstrate that our investigational product can bypass the effects of dual antiplatelet therapy (DAPT) by generating thrombin at sites of vascular injury, thereby restoring the hemostatic properties of patient platelets. Importantly, its effects could be reversed upon administration of a thrombin inhibitor. Thus, this product offers a titratable and reversible strategy for the management of defective hemostasis associated with DAPT.
Efimenko et al. (Mon,) conducted a other in Coronary artery disease requiring stenting on dual antiplatelet therapy (n=27). Freeze-dried, platelet-derived hemostatic agent (FPH) vs. Buffer control / No FPH was evaluated on Fraction of tails bleeding at 10 minutes in mice infused with DAPT-exposed human platelets (p=<0.001). A freeze-dried, platelet-derived hemostatic agent (FPH) restored hemostasis in humanized mice infused with DAPT-exposed platelets, reducing the fraction of bleeding tails at 10 minutes from 60% to 5%.